Engelmaier Andrea, Zimmermann Martin, Butterweck Harald A, Weber Alfred
Pharmaceutical Science, Baxalta Innovations GmbH, Part of Takeda, 1220 Vienna, Austria.
Plasma Derived Therapies R&D, Baxalta Innovations GmbH, Part of Takeda, 1220 Vienna, Austria.
Pharmaceuticals (Basel). 2025 Aug 6;18(8):1165. doi: 10.3390/ph18081165.
: The quality of clinical studies is largely determined by the bioanalytical methods used for testing study samples. Rigorous assay validation following defined criteria, for example, the European Medicines Agency guideline for bioanalytical method validation, is a prerequisite for such assays. Alpha1-antitrypsin (AAT) measurement, i.e., the specific measurement of AAT protein and its associated elastase-inhibitory activity, is an integral part of assay panels for clinical studies addressing AAT deficiency. Specifically, AAT must be measured in the matrix of citrated human plasma as well as in diluted solutions with high salt concentrations obtained through bronchoalveolar lavage (BAL). Sensitive and selective measurement methods are required, as BAL has a low level of AAT. : We present the validation data obtained for three AAT measurement methods. Two of them, nephelometry and the enzyme-linked immunosorbent assay, which clearly differ in their sensitivity, provide AAT protein concentrations. The third is the highly sensitive, newly developed elastase complex formation immunosorbent assay that specifically measures the inhibitory activity of AAT against its pivotal target, protease neutrophil elastase. Using samples with relevant AAT concentrations, we addressed the assays' characteristics: accuracy, precision, linearity, selectivity, specificity, limit of quantification and short-term analyte stability : Overall, the three methods demonstrated low total errors, a combined measure reflecting accuracy and precision, even at low analyte concentrations of less than 0.5 µg/mL; adequate linearity over the required assay range; and acceptable selectivity and specificity. Furthermore, the short-time stability of the analyte was also demonstrated. : All three AAT measurement methods met the acceptance criteria defined by the guidelines on bioanalytical assay validation, qualifying these methods for clinical sample analysis.
临床研究的质量很大程度上取决于用于检测研究样本的生物分析方法。遵循既定标准进行严格的分析方法验证,例如欧洲药品管理局生物分析方法验证指南,是此类分析的先决条件。α1-抗胰蛋白酶(AAT)测量,即对AAT蛋白及其相关弹性蛋白酶抑制活性的特异性测量,是针对AAT缺乏症的临床研究分析检测组的一个组成部分。具体而言,必须在枸橼酸化人血浆基质以及通过支气管肺泡灌洗(BAL)获得的高盐浓度稀释溶液中测量AAT。由于BAL中的AAT水平较低,因此需要灵敏且具有选择性的测量方法。
我们展示了三种AAT测量方法的验证数据。其中两种方法,散射比浊法和酶联免疫吸附测定法,在灵敏度上有明显差异,可提供AAT蛋白浓度。第三种是高度灵敏的新开发的弹性蛋白酶复合物形成免疫吸附测定法,它专门测量AAT对其关键靶标蛋白酶中性粒细胞弹性蛋白酶的抑制活性。我们使用具有相关AAT浓度的样本,研究了这些分析方法的特性:准确性、精密度、线性、选择性、特异性、定量限和分析物短期稳定性。
总体而言,这三种方法即使在低于0.5μg/mL的低分析物浓度下,也显示出较低的总误差(反映准确性和精密度的综合指标);在所需的分析范围内具有足够的线性;以及可接受的选择性和特异性。此外,还证明了分析物的短期稳定性。
所有三种AAT测量方法均符合生物分析方法验证指南中定义的验收标准,使这些方法有资格用于临床样本分析。